Showing results (81-90 of 126) with videos related to
Sort By:
Pageof 13
Blood Cancer Journal|August 1, 2015
PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantationY Kong, J Zhang, D F Claxton, et al.Pharmaceuticals (Basel, Switzerland)|October 28, 2023
Complementarity between Microbiome and Immunity May Account for the Potentiating Effect of Quercetin on the Antitumor Action of Cyclophosphamide in a Triple-Negative Breast Cancer ModelAndrea Manni, Yuan-Wan Sun, Todd D Schell, et al.Environmental Management|June 20, 2002
Assessing vulnerability to invasion by nonnative plant species at multiple spatial scalesThomas J Stohlgren, Geneva W Chong, Lisa D Schell, et al.Ophthalmic Plastic and Reconstructive Surgery|December 19, 2024
The Orbitomalar Ligament: A Cleavage Plane in Oculofacial TraumaMichael T Kryshtalskyj, Mina Mina, Carson D Schell, et al.Pharmacological Research|March 17, 2025
Managing telomerase and telomere dysfunction in acral melanomaVishnu Sravan Bollu, Yu-Chi Chen, Fan Zhang, et al.Journal of Virology|July 11, 2000
Quantitation of CD8(+) T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenesL M Mylin, T D Schell, D Roberts, et al.Scientific Reports|December 7, 2017
Mouse papillomavirus infection persists in mucosal tissues of an immunocompetent mouse strain and progresses to cancerNancy M Cladel, Lynn R Budgeon, Karla K Balogh, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 5, 2008
CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumorsAngela M Tatum, Lawrence M Mylin, Susan J Bender, et al.Elife|March 23, 2021
Effects of domestication on the gut microbiota parallel those of human industrializationAspen T Reese, Katia S Chadaideh, Caroline E Diggins, et al.Cancers|June 27, 2024
Targeting Tyro3, Axl, and MerTK Receptor Tyrosine Kinases Significantly Sensitizes Triple-Negative Breast Cancer to CDK4/6 InhibitionSeyma Demirsoy, Ha Tran, Joseph Liu, et al.Pageof 13